The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Liso-cel treatment in the outpatient setting

Aug 28, 2020

Lisocabtagene maraleucel (liso-cel; JCAR017) is an investigational anti-CD19 chimeric antigen receptor (CAR) T-cell product administered at equal target doses of CD8 +and CD4 +CAR T cells. The administration of liso-cel in the outpatient setting is allowed based on the discretion of the investigator and needs to follow standardized guidelines for safety monitoring and management. Outpatient administration provides multiple advantages, including making CAR T-cell therapy more accessible. 1

During the American Society of Clinical Oncology (ASCO) Virtual Meeting 2020, Carlos Bachier 1presented the results of a study evaluating the safety and efficacy of liso-cel in patients with relapsed/refractory large B-cell lymphoma (LBCL) who were monitored as outpatients at both university and non-university sites in three separate TRANSCEND studies: the phase I NHL-001 ( NCT02631044) and the phase II OUTREACH ( NCT03744676) and PILOT ( NCT03483103) trials.

Methods

After lymphodepletion with fludarabine (30 mg/m 2) and cyclophosphamide (300 mg/m 2) for 3 days, liso-cel was administered at either 50 × 10 6, 100 × 10 6, or 150 × 10 6CAR T cells for patients recruited on the TRANSCEND NHL-001 study, or at 100 × 10 6CAR T cells on the PILOT and OUTREACH studies.

Patients were considered outpatients if they received liso-cel infusion in the outpatient or inpatient setting and if they left the clinic or were discharged from the hospital at the end of the observation period on the day of infusion. Patients were required to receive safety monitoring education, have a caregiver, and stay within a one hour travel time to the site of care for 30 days posttreatment. All study sites had a multidisciplinary CAR T-cell team and standard operating procedures for toxicity management and monitoring.

Results

At data cutoff, 59 patients were treated and/or monitored as outpatients across the three studies (TRANSCEND  NHL 001, n = 25; OUTREACH, n = 22; and PILOT, n = 12) . Baseline demographics, safety outcomes, and response are reported in Table 1.

Table 1.Patient characteristics, safety outcomes, and response 1

CR, complete response; CRS, cytokine release syndrome; DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; FL3B, follicular lymphoma Grade 3B; HGBCL, high grade B-cell lymphoma; HSCT, hematopoietic stem cell transplant; NE, neurological event; ORR, overall response rate; PD, progressive disease; PMBCL, primary mediastinal B-cell lymphoma; PR, partial response; SD, stable disease; TEAE, treatment-emergent adverse event.

 

Outpatients

 

Inpatients

(n = 273)

TRANSCEND NHL 001

(n = 25)

OUTREACH

(n = 22)

PILOT

(n = 12)

Total

(n = 59)

Patient characteristics

Median age, years (range)

60 (24─82)

65 (50─83)

72 (58─80)

63 (24─83)

64 (18─86)

≥ 65, n (%)

7 (28)

11 (50)

10 (83)

28 (47)

127 (47)

Histology, n (%)

 

 

 

 

 

DLBCL not otherwise specified

14 (56)

17 (77)

7 (58)

38 (64)

136 (50)

DLBCL transformed from indolent histologies

5 (20)

5 (23)

0 (0)

10 (17)

78 (29)

HGBCL/PMBCL/FL3B

6 (24)

0 (0)

5 (42)

11 (19)

59 (22)

ECOG PS of 0 ─1/2 at screening, n (%)

25 (100)/0 (0)

22 (100)/0 (0)

9 (75)/3 (25)

56 (95)/3 (5)

263 (96)/10 (4)

Prior lines of therapy, median (range)

2 (1─5)

2 (2─5)

1 (1─1)

2 (1─5)

2 (1─8)

Prior HSCT, n (%)

9 (36)

7 (32)

0 (0)

16 (27)

10 (4)

Chemotherapy refractory, n (%)

16 (64)

16 (73)

6 (50)

38 (64)

184 (67)

Safety

TEAEs Grade 5, n (%)

0

0

0

0

8 (3)

CRS or NEs, n (%)

 

 

 

 

 

Any grade

15 (60)

10 (45)

0 (0)

25 (42)

124 (45)

Grade ≥ 3

2 (8)

1 (5)

0 (0)

3 (5)

29 (11)

CRS, n (%)

 

 

 

 

 

Any grade

12 (48)

9 (41)

0 (0)

21 (36)

111 (41)

Grade ≥ 3

1 (4)

0 (0)

0 (0)

1 (2)

5 (2)

NEs, n (%)

 

 

 

 

 

Any grade

11 (44)

6 (27)

0 (0)

17 (29)

75 (27)

Grade ≥ 3

2 (8)

1 (5)

0 (0)

3 (5)

27 (10)

Median time to CRS onset, days

5

4

Median time to NE onset, days

8

9

Median duration of CRS, days

5

5

Median duration of NEs, days

7

9

Tocilizumab or corticosteroid for CRS, n (%)

 

 

 

 

 

Tocilizumab only

0

0

0

0

28 (10)

Tocilizumab and corticosteroid

1 (4)

3 (14)

0

4 (7)

23 (8)

Corticosteroid only

2 (8)

0

0

2 (3)

3 (1)

Corticosteroids for NEs, n (%)

5 (20)

2 (9)

0

7 (12)

42 (15)

Best overall response, n (%)

ORR

20 (80)

16 (84)

11 (92)

47 (84)

189 (73)

CR

14 (56)

13 (68)

7 (58)

34 (61)

137 (53)

PR

6 (24)

3 (16)

4 (33)

13 (23)

52 (20)

SD

2 (8)

1 (5)

0 (0)

3 (5)

29 (11)

PD

3 (12)

2 (11)

1 (8)

6 (11)

28 (11)

Not evaluable

0 (0)

0 (0)

0 (0)

0 (0)

10 (4)

Hospitalization was required for 54% of outpatients, with a median length of stay of six days, and the main reasons for admission were cytokine release syndrome (CRS) and/or neurological events (17 patients) and other adverse events (15 patients). Two patients required treatment in the intensive care unit: one for CRS and one for dehydration.

Conclusion

The safety profile of liso-cel following outpatient administration showed no increase in rates of severe CRS or other adverse events when compared to inpatient administration. These data, together with the similar efficacy rates observed between the outpatient and inpatient settings, support outpatient liso-cel administration for patients with relapsed/refractory LBCL, provided that the proper safety monitoring and standard operating protcols are being followed. Outpatient administration and monitoring of liso-cel continue to be evaluated and further data are expected to further validate these results.

  1. Bachier C, Godwin J, Andreadis C, et al. Outpatient treatment with lisocabtagene maraleucel (liso-cel) across a variety of clinical sites from three ongoing clinical studies in relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Poster #8037. ASCO Annual Meeting; May 2020; Virtual.